TSE:4502Pharmaceuticals
Takeda Pharmaceutical’s Valuation After ENTYVIO Pediatric Data And TAK-861 Priority Review
Regulatory momentum in gastroenterology and neuroscience
Takeda Pharmaceutical (TSE:4502) has drawn fresh investor attention after reporting positive Phase 3 KEPLER trial data for ENTYVIO in pediatric ulcerative colitis and securing FDA Priority Review for its narcolepsy type 1 candidate TAK-861.
See our latest analysis for Takeda Pharmaceutical.
These pipeline updates have arrived alongside a strong run in the share price, with Takeda Pharmaceutical posting a 30 day share price return of...